WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:
   (i) a diluent;
   (ii) a glidant;
   (iii)a lubricant; and optionally
   (iv)a disintegrant.
2. The pharmaceutical composition of claim 1, wherein the composition is formulated as a solid dosage form.
3. The pharmaceutical composition of any one of claims 1-2, wherein the composition is formulated as a capsule, a pill, a cachet, a tablet, a granule, a multi-particulate, a mini-tablet, or powder.
4. The pharmaceutical composition of any one of claims 1-3, wherein the composition is formulated as a tablet.
5. The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises about 5 mg to about 50 mg maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.
6. The pharmaceutical composition of any one of claims 1-5, wherein the composition comprises 5% to 40% (w/w) maralixibat, or 10% to 25% (w/w) maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.
7. The pharmaceutical composition of any one of claims 1-6, wherein the composition comprises maralixibat chloride.
8. The pharmaceutical composition of any one of claims 1-7, wherein the maralixibat, or a pharmaceutically acceptable salt thereof is loop milled or pin milled.
9. The pharmaceutical composition of any one of claims 1-8, wherein the particle size distribution of the maralixibat, or a pharmaceutically acceptable salt thereof has a Dv90 of less than about 850 μm, or less than about 100 μm, or less than about 60 μm.
10. The pharmaceutical composition of any one of claims 1-9, comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:
    (i) a diluent;
    (ii) a glidant in an amount of 0.1 to 2% (w/w);

(iii) a lubricant in an amount of 6% to 12% (w/w); and

(iv) a disintegrant in an amount of 1% to 10% (w/w).

11. The pharmaceutical composition of any one of claims 1-9, wherein the composition comprises 0.2% to 12% (w/w) lubricant.

12. The pharmaceutical composition of any one of claims 1-11, wherein the lubricant is selected from the group consisting of magnesium stearate, talc, calcium stearate, zinc stearate, sodium stearate, sodium stearyl fumarate, sodium lauryl sulfate, stearic acid, aluminum stearate, leucine, glyceryl behenate, glyceryl dibehenate, glyceryl palmitostearate, hydrogenated vegetable oil, and any combinations thereof.

13. The pharmaceutical composition of any one of claims 1-12, wherein the composition comprises 1% to 10% (w/w), or 3% to 7% (w/w) disintegrant.

14. The pharmaceutical composition of any one of claims 1-13, wherein the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof.

15. The pharmaceutical composition of any one of claims 1-14, wherein the composition comprises 0.1 to 2% (w/w), or 0.5% (w/w) glidant.

16. The pharmaceutical composition of any one of claims 1-15, wherein the glidant is selected from the group consisting of silicon dioxide, magnesium stearate, talc, corn starch, and any combinations thereof.

17. The pharmaceutical composition of any one of claims 1-16, wherein the composition comprises 65% to 90%, or 65% to 80%, or 70% to 85%, or 70% to 80% (w/w) diluent.

18. The pharmaceutical composition of any one of claims 1-17, wherein the diluent is selected from the group consisting of a sugar, dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, starch, cellulose, and modified celluloses, and any combination thereof.

19. The pharmaceutical composition of any one of claims 1-18, further comprising a binder.

20. The pharmaceutical composition of claim 19, wherein the binder is polyvinylpyrrolidone (povidone), dibasic calcium phosphate, sucrose, corn starch, modified cellulose, hydroxypropyl methylcellulose E3 (HPMC E3), or a combination thereof.

21. The pharmaceutical composition of any one of claims 1-20, further comprising one or more excipients selected from the group consisting of:

(i) a solubilizing agent;

(ii) a channeling agent;

(iii)a chelating agent; and

(iv)a film coating agent.

22. The pharmaceutical composition of any one of claims 1-21, comprising about 10.5% (w/w) maralixibat chloride and

(i) about 50% (w/w) MCC and about 25% (w/w) lactose monohydrate;

(ii) about 0.5% (w/w) silicon dioxide;

(iii) about 9% (w/w) glyceryl palmitostearate; and

(iv) about 5% (w/w) crospovidone.

23. The pharmaceutical composition of claim 22, wherein the composition comprises 5mg to 50 mg maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.

24. The pharmaceutical composition of claim 23, wherein the composition comprises about 5mg, about 10 mg, about 30 mg, or about 50 mg maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.

25. The pharmaceutical composition of any one of claims 1-24, wherein the composition is stable at room temperature and 60% relative humidity (RH) for at least 6 months.

26. The pharmaceutical composition of any one of claims 1-23, wherein the composition is stable at 40°C and 75% RH for at least 6 months, or at least 12 months, or at least 24 months, or at least 36 months.

27. Use of the pharmaceutical composition of any one of claims 1-26 in the manufacture of a medicament for treating cholestatic pruritus in a subject in need thereof.

28. The use of claim 27, wherein the cholestatic pruritus is associated with Alagille syndrome (ALGS), wherein the subject has Alagille syndrome, wherein the subject is a pediatric subject between 2 months and 18 years of age, or wherein the subject is an adult who is 18 years of age or older.

29. Use of the pharmaceutical composition of any one of claims 1-26 in the manufacture of a medicament for treating cholestatic liver disease or condition in a subject in need thereof.

30. The use of claim 29, wherein the cholestatic liver disease or condition is selected from the group consisting of obstructive cholestasis, non-obstructive cholestasis, extrahepatic

cholestasis, intrahepatic cholestasis, primary intrahepatic cholestasis, secondary intrahepatic cholestasis, progressive familial intrahepatic cholestasis (PFIC), PFIC type 1, PFIC type 2, PFIC type 3, PFIC type 4, PFIC type 5, PFIC type 6, benign recurrent intrahepatic cholestasis (BRIC), BRIC type 1, BRIC type 2, BRIC type 3, total parenteral nutrition associated cholestasis, paraneoplastic cholestasis, Stauffer syndrome, intrahepatic cholestasis of pregnancy, contraceptive-associated cholestasis, drug-associated cholestasis, infection-associated cholestasis, Dubin-Johnson Syndrome, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), gallstone disease, Alagille syndrome, Dubin-Johnson Syndrome, biliary atresia, post-Kasai biliary atresia, post-liver transplantation biliary atresia, post-liver transplantation cholestasis, post-liver transplantation associated liver disease, intestinal failure associated liver disease, bile acid mediated liver injury, MRP2 deficiency syndrome, and neonatal sclerosing cholangitis.